Intravenous dexmedetomidine infusion in healthy males produced a transient increase in mean arterial blood pressure followed by a dose-dependent decrease of up to 27% at 60 minutes (P<0.05).
RCT (n=37)
double-blind
randomized
Does intravenous dexmedetomidine alter hemodynamic parameters in healthy male volunteers?
A 2-minute intravenous infusion of dexmedetomidine in healthy males produces a transient initial increase followed by a longer-lasting decrease in blood pressure and catecholamines, and is well tolerated.
p-value: p=<.05
Dexmedetomidine (DMED) is a novel clonidine-like compound known to have sedative, analgesic, and cardiovascular stabilizing qualities. DMED is a more highly selective alpha 2-adrenergic agonist than clonidine. This investigation examined the hemodynamic effects of four selected iv doses in consenting healthy male volunteers. In a randomized, double-blind, placebo-controlled trial subjects received 0 (n = 9), 0.25 (n = 6) 0.5 (n = 6), 1.0 (n = 6), or 2.0 (n = 10) micrograms/kg of DMED by infusion (2 min). ECG, heart rate (HR), arterial blood pressure (MABP), bioimpedance cardiac output (CO), and plasma catecholamines concentrations (CA) were monitored from 90 min before to 360 min after infusion. Plasma DMED concentrations were measured. DMED produced a maximum decrease in MABP at 60 min of 14%, 16%, 23%, and 27% for the 0.25, 0.5, 1.0, and 2.0 micrograms/kg groups, respectively (P < .05). At 330 min MABP remained below baseline by 8% and 17% at the two largest doses (P < .05). Both HR and CO decreased maximally by both 17% at 105 min. The two largest doses produced a transient (peak at 3 min lasting < 11 min) increased in MABP (16 +/- 2.5 and 24 +/- 10 mmHg, respectively; P < .05) with a concomitantly reduced CO (41%, 2 micrograms/kg; P < .05) and HR (22%, 2 micrograms/kg; P < .05), whereas systemic vascular resistance doubled. Even the lowest dose decreased CA immediately to values close to 20 pg/ml for 5 h. A 2-min iv infusion of DMED produced a transient increase in MABP and a longer lasting decrease in MABP and CA. These DMED doses were well tolerated in the healthy volunteers.
Bloor et al. (Mar,) ont mené un ECR chez des volontaires sains (n=37). La dexmédétomidine (DMED) vs. Placebo a été évaluée sur les effets hémodynamiques, y compris la pression artérielle artérielle moyenne (PAM), la fréquence cardiaque et le débit cardiaque (p=<.05). L'infusion intraveineuse de dexmédétomidine chez des hommes sains a produit une augmentation transitoire de la pression artérielle artérielle moyenne suivie d'une diminution dose-dépendante allant jusqu'à 27 % à 60 minutes (P<0.05).